Kidney Week 2015 General Coverage
Analysis of data from the HALT PKD trial showed that 0% to 0.4% of patients experienced potassium levels above 6.5 mEq/L.
Having hemoglobin 9-11 g/dL prior to dialysis provided the best life expectancy.
It is unclear whether RDW is a risk factor for early death or a byproduct of biological and metabolic imbalances.
Veteran patients with levels below 100 mg/dL had a 26% higher risk of mortality compared with patients with triglyceride levels of 150-200 mg/dL.
Up to 100 mg per day raises plasma concentrations of ascorbic acid without increasing oxalate levels.
Patients prescribed the lipid-lowering agents were less likely to exhibit hyporesponsiveness to the medications.
Study finds no gender differences in parathyroid hormone, ferritin, Kt/V, or age.
In a study, the mean hemoglobin level increased significantly in hemodialysis patients with functional iron deficiency.
In an 8-week randomized trial, extended-release nalbuphine 120 mg BID significantly reduced itch severity compared with placebo.
In a 24-hour exploratory trial, all 7 patients who wore the device remained hemodynamically stable over the study period.
Renal and Urology News Articles
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
- PET/CT May Improve Imaging of Recurrent Prostate Cancer
- Adding MRI Does Not Boost Prostate Cancer Upgrading Rate
- Both High and Low Uric Acid Levels Tied to Higher Mortality
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)